-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $10 Price Target

Benzinga·03/12/2026 15:18:37
Listen to the news
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $10 price target.